STOCK TITAN

Avenue Therapeutics Inc - ATXI STOCK NEWS

Welcome to our dedicated news page for Avenue Therapeutics (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avenue Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avenue Therapeutics's position in the market.

Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) reported financial results and recent corporate highlights for the third quarter ended September 30, 2023. The company's Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA) remains on track to report topline data in the second quarter of 2024. Positive BAER-101 preclinical data has been accepted for presentation at the American Epilepsy Society Annual Meeting. Avenue also reached an agreement with the U.S. FDA on the study design and analysis approach for the Phase 3 safety study of IV tramadol. The company raised $5 million in gross proceeds from a public equity offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
earnings
-
Rhea-AI Summary
Avenue Therapeutics, Inc. has closed its public offering, raising approximately $5.0 million. The offering consisted of 16,633,400 units at a price of $0.3006 per unit. Each unit included one share of common stock, one Series A warrant, and one Series B warrant. Maxim Group LLC and Lake Street Capital Markets, LLC acted as placement agents for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
offering
-
Rhea-AI Summary
Avenue Therapeutics, Inc. has announced the pricing of its public offering of 16,633,400 units at a price of $0.3006 per unit. Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant. The gross proceeds from the offering are expected to be approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.05%
Tags
offering
Rhea-AI Summary
Avenue Therapeutics CEO to present corporate update at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
conferences
-
Rhea-AI Summary
Avenue Therapeutics reports progress in clinical trials and agreement with FDA on study design for IV tramadol. First patient dosed in Phase 1b/2a trial of AJ201 for SBMA. Positive preclinical data for BAER-101 in epilepsy. Financial results show decrease in cash and increase in expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
earnings
-
Rhea-AI Summary
Avenue Therapeutics announces positive preclinical results for BAER-101 in epilepsy treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
clinical trial
Rhea-AI Summary
Avenue Therapeutics announces the dosing of the first patient in the Phase 1b/2a clinical trial of AJ201 for the treatment of SBMA. The trial is expected to be completed by the end of 2023 or early 2024, with potential topline data in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
clinical trial
-
Rhea-AI Summary
Avenue Therapeutics has reached an agreement with the FDA on key elements of the Phase 3 safety study for its intravenous tramadol, which is being developed for the treatment of acute post-operative pain. The study will assess the risk of opioid-induced respiratory depression compared to IV morphine. The company believes that IV tramadol will prove to be safe and effective based on its mechanism of action and positive data from previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
Avenue Therapeutics Inc

Nasdaq:ATXI

ATXI Rankings

ATXI Stock Data

6.53M
39.44M
10.88%
2.8%
0.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ATXI

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.